Landfar Bio-medicine Co., Ltd Stock

Equities

000504

CNE000000263

Healthcare Facilities & Services

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
7.25 CNY +10.02% Intraday chart for Landfar Bio-medicine Co., Ltd -7.29% -37.50%
Sales 2021 157M 21.63M Sales 2022 200M 27.67M Capitalization 3.63B 501M
Net income 2021 -19M -2.62M Net income 2022 -12M -1.66M EV / Sales 2021 38 x
Net Debt 2021 154M 21.31M Net Debt 2022 16.5M 2.28M EV / Sales 2022 18.2 x
P/E ratio 2021
-310 x
P/E ratio 2022
-291 x
Employees 512
Yield 2021 *
-
Yield 2022
-
Free-Float 51.63%
More Fundamentals * Assessed data
Dynamic Chart
Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million. CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Landfar Bio Medicine’s Controlling Shareholder Boosts Stake to 30% MT
Landfar Bio-medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Landfar Bio-medicine Co., Ltd completed the acquisition of additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd. from Wang Yang, Luo Yi and Changsha Aishi Pulin Information Consulting Co., Ltd. for CNY 9.7 million. CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
NanHua Bio-medicine Co., Ltd announced that it expects to receive CNY 275.999987 million in funding from Hunan Chasing Fund Management Co., Ltd. CI
NanHua Bio-medicine Co., Ltd signed a letter of intent to acquire Medicine-related assets from YanAn Bicon Pharmaceutical Listed Company. CI
NanHua Bio-medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Nanhua Bio-Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news
1 day+10.02%
1 week-7.29%
Current month-16.18%
1 month-22.38%
3 months-28.99%
6 months-31.02%
Current year-37.50%
More quotes
1 week
6.25
Extreme 6.25
7.80
1 month
6.25
Extreme 6.25
10.04
Current year
5.26
Extreme 5.26
12.18
1 year
5.26
Extreme 5.26
13.17
3 years
5.26
Extreme 5.26
24.97
5 years
5.26
Extreme 5.26
24.97
10 years
5.26
Extreme 5.26
36.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 20-06-16
Director of Finance/CFO 51 15-01-26
Investor Relations Contact - -
Members of the board TitleAgeSince
Chief Executive Officer 51 20-06-16
Director/Board Member 53 21-12-28
Director/Board Member 43 17-11-29
More insiders
Date Price Change Volume
24-04-18 7.25 +10.02% 7,946,500
24-04-17 6.59 +3.78% 4,351,517
24-04-16 6.35 -9.93% 3,560,090
24-04-15 7.05 -9.96% 5,382,100
24-04-12 7.83 +0.13% 2,220,240

End-of-day quote Shenzhen S.E., April 17, 2024

More quotes
Landfar Bio medicine Co Ltd is a China-based company mainly engaged in the biomedical and energy conservation & environmental protection business. The Company’s biomedical business includes stem cell storage and technical services, stem cell treatment research, medical instrument purchasing & sales. The Company’s energy conservation & environmental protection business includes energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The Company is involved in other businesses related to aid and build project. The Company mainly conducts businesses within the domestic market.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000504 Stock